Author

N. K. Mair

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Scientific Communication & Education· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

B. G. Hale· 1 shared D. Eletto· 1 shared E. Moritz· 1 shared I. Busnadiego· 1 shared J. Börold· 1 shared J. Gottowik· 1 shared M. Schwemmle· 1 shared N. Schmidt· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

B. G. Hale

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Characteristics and data reporting of rare disease clinical trials: Getting better but still room for improvement

N. K. Mair, J. Gottowik, R. Rodriguez-Esteban, T. J. Seabrook

This paper analyzes rare disease clinical trials, finding that while some improvements have been made, result reporting remains inadequate, with many trials not disclosing results on ClinicalTrials.gov.

bioRxiv · Dec 3, 2021 · PreprintScientific Communication & Education

Genome-Wide CRISPR Screening Identifies BRD9 as a Druggable Component of Interferon-Stimulated Gene Expression and Antiviral Activity

J. Börold, D. Eletto, I. Busnadiego, N. K. Mair, E. Moritz, S. Schiefer, N. Schmidt, P. P. Petric, W. W.-L. Wong, M. Schwemmle, B. G. Hale

This study identifies BRD9 as a critical component of IFN signaling and antiviral activity through CRISPR screening, showing its druggability for targeting constitutive ISG expression.

bioRxiv · Feb 4, 2021Immunology